secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001193125-23-271921
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Biotherapeutics Q3 net loss $7.1M; cash $72M; SNS-101 Phase 1 data positive
--------------------------------------------------------------------------------

- Net loss $7.1M in Q3 2023 vs $13.4M in Q3 2022; cash $72.0M as of Sept 30, 2023, down from $107.1M at Dec 31, 2022.
- R&D expenses $3.8M vs $9.2M YoY; G&A $3.9M vs $4.8M; cash runway expected into H2 2025.
- SNS-101 Phase 1 data at SITC: no cytokine release syndrome, no dose-limiting toxicities, dose-proportional pharmacokinetics.
- Enrollment ahead of schedule: 17 patients treated; monotherapy dose escalation at 15 mg/kg; combination arm cleared 3 mg/kg.
- Apped Stephanie Krebs as CBO; SNS-201 and SNS-102 lead candidates selected; milestones: combo data Q1 2024, monotherapy topline Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/0001193125-23-271921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312523271921/d908748d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-271921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer